147 related articles for article (PubMed ID: 1615580)
1. Differential sensitivity of hormone-responsive and unresponsive human prostate cancer cells (LNCaP) to tumor necrosis factor.
Zhao X; van Steenbrugge GJ; Schröder FH
Urol Res; 1992; 20(3):193-7. PubMed ID: 1615580
[TBL] [Abstract][Full Text] [Related]
2. The human prostatic carcinoma cell line LNCaP and its derivatives. An overview.
van Steenbrugge GJ; Groen M; van Dongen JW; Bolt J; van der Korput H; Trapman J; Hasenson M; Horoszewicz J
Urol Res; 1989; 17(2):71-7. PubMed ID: 2660395
[TBL] [Abstract][Full Text] [Related]
3. Variants of the human prostate LNCaP cell line as tools to study discrete components of the androgen-mediated proliferative response.
Soto AM; Lin TM; Sakabe K; Olea N; Damassa DA; Sonnenschein C
Oncol Res; 1995; 7(10-11):545-58. PubMed ID: 8866667
[TBL] [Abstract][Full Text] [Related]
4. The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen sensitivity.
van Steenbrugge GJ; van Uffelen CJ; Bolt J; Schröder FH
J Steroid Biochem Mol Biol; 1991; 40(1-3):207-14. PubMed ID: 1958522
[TBL] [Abstract][Full Text] [Related]
5. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
6. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.
Sokoloff MH; Tso CL; Kaboo R; Taneja S; Pang S; deKernion JB; Belldegrun AS
Cancer; 1996 May; 77(9):1862-72. PubMed ID: 8646686
[TBL] [Abstract][Full Text] [Related]
7. Androgens inhibit the proliferation of a variant of the human prostate cancer cell line LNCaP.
Joly-Pharaboz MO; Soave MC; Nicolas B; Mebarki F; Renaud M; Foury O; Morel Y; Andre JG
J Steroid Biochem Mol Biol; 1995 Oct; 55(1):67-76. PubMed ID: 7577722
[TBL] [Abstract][Full Text] [Related]
8. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
9. Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells.
Hara T; Kouno J; Nakamura K; Kusaka M; Yamaoka M
Prostate; 2005 Nov; 65(3):268-75. PubMed ID: 16015592
[TBL] [Abstract][Full Text] [Related]
10. LNCaP prostatic adenocarcinoma cells derived from low and high passage numbers display divergent responses not only to androgens but also to retinoids.
Esquenet M; Swinnen JV; Heyns W; Verhoeven G
J Steroid Biochem Mol Biol; 1997 Aug; 62(5-6):391-9. PubMed ID: 9449242
[TBL] [Abstract][Full Text] [Related]
11. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
Zhao XY; Ly LH; Peehl DM; Feldman D
Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780
[TBL] [Abstract][Full Text] [Related]
12. Vitamin E and other antioxidants inhibit human prostate cancer cells through apoptosis.
Gunawardena K; Murray DK; Meikle AW
Prostate; 2000 Sep; 44(4):287-95. PubMed ID: 10951493
[TBL] [Abstract][Full Text] [Related]
13. Role of growth factors, steroid and peptide hormones in the regulation of human prostatic tumor growth.
Motta M; Dondi D; Moretti RM; Montagnani Marelli M; Pimpinelli F; Maggi R; Limonta P
J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):107-11. PubMed ID: 8603030
[TBL] [Abstract][Full Text] [Related]
14. Androgen and taxol cause cell type-specific alterations of centrosome and DNA organization in androgen-responsive LNCaP and androgen-independent DU145 prostate cancer cells.
Schatten H; Ripple M; Balczon R; Weindruch R; Chakrabarti A; Taylor M; Hueser CN
J Cell Biochem; 2000 Jan; 76(3):463-77. PubMed ID: 10649443
[TBL] [Abstract][Full Text] [Related]
15. Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP.
Langeler EG; van Uffelen CJ; Blankenstein MA; van Steenbrugge GJ; Mulder E
Prostate; 1993; 23(3):213-23. PubMed ID: 7694266
[TBL] [Abstract][Full Text] [Related]
16. Antiproliferative activity of casodex (ICI 176.334) in hormone-dependent tumours.
Maucher A; von Angerer E
J Cancer Res Clin Oncol; 1993; 119(11):669-74. PubMed ID: 8349724
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of antiproliferative effects of interleukin-1beta and tumor necrosis factor-alpha on human prostate cancer LNCaP cells by coculture with normal fibroblasts through secreted interleukin-6.
Kawada M; Ishizuka M; Takeuchi T
Jpn J Cancer Res; 1999 May; 90(5):546-54. PubMed ID: 10391095
[TBL] [Abstract][Full Text] [Related]
18. Estrogens affect endothelin-1 mRNA expression in LNCaP human prostate carcinoma cells.
Grande M; Carlström K; Stege R; Pousette A; Faxén M
Eur Urol; 2002 May; 41(5):568-72; discussion 573-4. PubMed ID: 12074801
[TBL] [Abstract][Full Text] [Related]
19. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
[TBL] [Abstract][Full Text] [Related]
20. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells.
Wu HC; Hsieh JT; Gleave ME; Brown NM; Pathak S; Chung LW
Int J Cancer; 1994 May; 57(3):406-12. PubMed ID: 8169003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
